UK based Scan.com Raises $90M Equity in Early-Stage Health Rounds

Scan.com, the UK founded diagnostic imaging platform, has closed 220 million dollars in combined equity and debt financing, comprising a 90 million dollar Series C equity round alongside 130 million dollars in debt facilities, marking one of the largest early‑stage health financings raised by a UK company to date.

The equity portion was led by Noteus Partners, a French growth equity firm focused on scaling high‑growth technology platforms, with participation from Aviva, Concord Health Partners, YZR Capital, and Oxford Capital, among others. The 130 million dollars in debt facilities, earmarked to support acquisitions and working capital, was provided by VerisFi Capital and Atempo Growth. The round follows Scan.com's earlier Series A, a 12 million dollar raise backed by Monzo co‑founder Tom Blomfield alongside Aviva, YZR Capital, Oxford Capital, Triple Point, and Simplyhealth, meaning several of the company's earliest institutional backers have now returned across multiple funding rounds.

Scan.com was founded in 2021 by chief executive Charlie Bullock alongside Oliver Knight and Joe Daniels, joined by osteopath Jasper Nissim and consultant radiologist Khalid Latief. The company's original idea grew out of the extreme wait times NHS patients often faced when needing medical scans, ranging from MRIs to ultrasounds to X‑rays, a problem compounded by the high cost, complexity, and administrative burden involved in booking scanning equipment across a fragmented network of independent imaging centres. Scan.com's original UK platform aggregated hundreds of scanning centres into a single booking system, guaranteeing patients a consultation within 48 hours rather than the weeks or months typical of the traditional pathway.

The company has since expanded that model into the United States, where it now generates the majority of its revenue and bases roughly 80 percent of its workforce. Bullock has framed the scale of the American opportunity in stark terms. "The US runs around 600 million medical imaging scans a year, and there is still no national infrastructure behind them," he said. "Labs got that decades ago with Quest Diagnostics and Labcorp. Imaging never did, and that is what we have built. An employer, a health plan or a digital health app can now connect to imaging capacity nationwide through a single API, and their patients get scanned at a quality‑checked centre in days rather than weeks, at a price they can see before they schedule. This investment is about making that the standard in US healthcare, rather than the exception."

The US medical imaging market Scan.com is targeting is valued at more than 100 billion dollars and is projected to grow to just over 121 billion dollars by 2033, according to forecasts from Grand View Research. Despite that scale, the market remains notably fragmented, slow, and largely offline, with roughly 85 percent of scans still booked via fax or phone rather than digitally. Patients frequently wait weeks for an appointment, a problem compounded by a national shortage of radiologists and imaging technologists. Pricing opacity adds a further layer of dysfunction: Scan.com's own data shows that the identical MRI scan can cost a few hundred dollars at one imaging centre and several thousand dollars at another located just a few miles away, with price bearing little relationship to underlying quality.

Scan.com's answer is a single application programming interface, or API, that connects employers, health plans, and digital health apps directly to imaging capacity across a national network of quality‑checked centres, allowing patients to be scanned in days rather than weeks at a price visible before they schedule the appointment. Industry analysis of the round has noted that the network label Scan.com is claiming does not come without real work behind it, and that the company's stated ambition rests on proving it can deliver genuinely national coverage through that unified API rather than remaining a patchwork of regional partnerships.

The scale of investor backing behind the round carries a notable signal for UK pension capital specifically. Ant Barker, director of venture capital at Aviva Investors, pointed to the broader significance of continued institutional participation in Scan.com's growth. "[Scan.com is] one of the fastest‑growing companies in our venture capital portfolio, and well placed to deliver long‑term returns for UK savers and institutional investors," Barker said, noting that UK pension funds increasingly want greater access to high‑growth, unlisted companies "that build tomorrow's technologies and create social value." That framing connects directly to the UK's Mansion House Compact, under which nine of the country's largest pension providers have committed to allocate 5 percent of their default fund assets to unlisted equities by 2030, a policy shift explicitly aimed at channelling more UK institutional capital into exactly the kind of high‑growth private company Scan.com represents.

Scan.com says it has doubled revenue over the past year, surpassing a 165 million dollar annualized run rate while serving more than 900,000 patients globally across both the US and UK. That growth trajectory, combined with the scale and structure of this latest financing, comes with open discussion of an eventual public listing, according to industry commentary on the deal, positioning Scan.com among a small group of UK‑founded healthtech companies pursuing a genuine dual‑market strategy of scaling domestically while building toward US market leadership in a category, medical imaging infrastructure, that has historically lagged well behind comparable diagnostic categories like clinical laboratory testing in terms of digital, networked infrastructure. Whether Scan.com can translate its UK‑proven model into the considerably larger and more fragmented US market at the pace its new capital anticipates will be the central test determining whether this round marks a genuine inflection point toward IPO readiness or simply another well‑funded chapter in a longer international expansion story.